Latest revenue
$110.0K
as of 2026-03-31
Latest net income
$-20.7M
as of 2026-03-31
Net margin
-18810.0%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $243.1M
- Enterprise value
- $243.1M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $5.42
- 52-wk low
- $2.20
- Beta
- —
- Shares out
- 59.9M
5-year trend
What this company does
Item 1. Business Our Vision Our vision is to accelerate medical innovation to patients through risk-reward-sharing partnerships with leading medical device companies. Our Company We are a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. We are led by a highly accomplished, multidisciplinary management team and a board of directors with extensive experience in all phases of therapeutic device development. Our business was formed in 2018 by assembling a pipeline of multiple late-stage clinical product candidates originally developed by our founding team. Our flagship product…
AI summary unavailable — showing raw filing excerpt
Generated from OBIO's filing dated 2026-03-12
Key risks
Item 1A. Risk Factors Our business involves a high degree of risk. You should consider and read carefully all of the risks and uncertainties described below, as well as other information included in this Annual Report on Form 10-K, including our audited consolidated financial statements and related notes appearing in Item 8 of this Annual Report on Form 10-K. The risks described below are not the only ones facing us. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition or results of operations. In such case, the trading…
AI summary unavailable — showing raw filing excerpt
Generated from OBIO's filing dated 2026-03-12
Profitability
Operating margin
-154.7%
93.7%Net margin
-157.4%
93.2%Return on equity
483.9%
4936.7%Return on assets
-45.9%
42.7%Leverage
Debt / equity
-10.80×
74.3%Long-term debt / equity
-1.37×
Debt / assets
110.2%
7.6%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $110.0K | -87.3% | $-20.7M | -10.3% | -18810.0% |
Q4 2025 2025-12-31 | $30.9M | +12120.2% | $6.2M | +138.7% | 20.2% |
Q3 2025 2025-09-30 | $861.0K | -12.8% | $-20.8M | -35.0% | -2419.0% |
Q2 2025 2025-06-30 | $836.0K | +7.5% | $-19.4M | -21.2% | -2316.1% |
Q1 2025 2025-03-31 | $868.0K | +40.0% | $-18.8M | -39.3% | -2160.7% |
Q4 2024 2024-12-31 | $253.0K | — | $-16.2M | — | -6385.4% |
Q3 2024 2024-09-30 | $987.0K | +135.6% | $-15.4M | -15.8% | -1562.9% |
Q2 2024 2024-06-30 | $778.0K | -15.0% | $-16.0M | -32.7% | -2054.0% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on OBIO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$16.4M
Insider selling
$8.3K
Net activity
+$16.3M
Distinct insiders
7
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns OBIO
Institutional value
$16.4M
Total shares held
3.8M
Distinct holders
24
-39 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $9.4M | — | New |
| 2 | BlackRock, Inc. | 635.7K | $2.7M | +4.8K (+0.8%) | Added |
| 3 | VANGUARD FIDUCIARY TRUST CO | 235.2K | $999.7K | — | New |
| 4 | Simplify Asset Management Inc. | 219.4K | $932.4K | — | New |
| 5 | IFP Advisors, Inc | 98.9K | $420.3K | +12.2K (+14.1%) | Added |
| 6 | Hudson Bay Capital Management LP | 71.1K | $302.3K | +21.7K (+43.9%) | Added |
| 7 | JANE STREET GROUP, LLC | 55.7K | $236.6K | -118.1K (-68.0%) | Trimmed |
| 8 | Daytona Street Capital LLC | 52.6K | $235.4K | +31.1K (+144.7%) | Added |
| 9 | Holos Integrated Wealth LLC | 51.6K | $219.8K | +0 (+0.0%) | No change |
| 10 | UBS Group AG | 50.3K | $213.8K | +38.9K (+341.7%) | Added |
| 11 | Meramec Financial Planners, LLC | 30.0K | $130.5K | +0 (+0.0%) | No change |
| 12 | Catalyst Funds Management Pty Ltd | 27.6K | $117.5K | — | New |
| 13 | CITIGROUP INC | 25.5K | $108.5K | +6.1K (+31.2%) | Added |
| 14 | Cannon Global Investment Management, LLC | 22.6K | $96.1K | — | New |
| 15 | HighTower Advisors, LLC | 18.3K | $77.7K | +0 (+0.0%) | No change |
| 16 | Vanguard Global Advisers, LLC | 13.9K | $59.3K | — | New |
| 17 | ABLE Financial Group, LLC | 13.4K | $57.0K | +0 (+0.0%) | No change |
| 18 | China Universal Asset Management Co., Ltd. | 10.0K | $42.6K | +819 (+8.9%) | Added |
| 19 | JPMORGAN CHASE & CO | 4.3K | $17.3K | -328 (-7.2%) | Trimmed |
| 20 | Mirae Asset Global Investments Co., Ltd. | 2.9K | $12.5K | +201 (+7.3%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once OBIO's latest filing finishes processing.